242 related articles for article (PubMed ID: 15549226)
1. [Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA].
Stroszczynski C; Gaffke G; Gnauck M; Streitparth F; Wieners G; Lopez-Häninnen E
Radiologe; 2004 Dec; 44(12):1185-91. PubMed ID: 15549226
[TBL] [Abstract][Full Text] [Related]
2. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
3. Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study.
Dahlqvist Leinhard O; Dahlström N; Kihlberg J; Sandström P; Brismar TB; Smedby O; Lundberg P
Eur Radiol; 2012 Mar; 22(3):642-53. PubMed ID: 21984449
[TBL] [Abstract][Full Text] [Related]
4. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA.
Runge VM
J Comput Assist Tomogr; 1998; 22(4):643-50. PubMed ID: 9676461
[TBL] [Abstract][Full Text] [Related]
5. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
6. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
[TBL] [Abstract][Full Text] [Related]
7. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
Giovagnoni A; Paci E
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717
[TBL] [Abstract][Full Text] [Related]
8. Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: Quantitative and qualitative analysis.
Yeom SK; Byun JH; Kim HJ; Park SH; Kim N; Shin YM; Kim PN
Magn Reson Imaging; 2013 Jul; 31(6):911-7. PubMed ID: 23598063
[TBL] [Abstract][Full Text] [Related]
9. Comparison of gadoxetic acid to gadobenate dimeglumine for assessment of biliary anatomy of potential liver donors.
Lewis S; Vasudevan P; Chatterji M; Besa C; Jajamovich G; Facciuto M; Taouli B
Abdom Radiol (NY); 2016 Jul; 41(7):1300-9. PubMed ID: 26960727
[TBL] [Abstract][Full Text] [Related]
10. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced MRI of the liver in Mrp2-deficient rats using the hepatobiliary contrast agent Gd-EOB-DTPA.
Saito S; Obata A; Kashiwagi Y; Abe K; Murase K
Invest Radiol; 2013 Jul; 48(7):548-53. PubMed ID: 23442774
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
Feuerlein S; Gupta RT; Boll DT; Merkle EM
Eur J Radiol; 2012 Sep; 81(9):2037-41. PubMed ID: 21719224
[TBL] [Abstract][Full Text] [Related]
13. Lesion detection and assessment of extrahepatic findings in abdominal MRI using hepatocyte specific contrast agents--comparison of Gd-EOB-DTPA and Gd-BOPTA.
Ringe KI; Boll DT; Husarik DB; Bashir MR; Gupta RT; Merkle EM
BMC Med Imaging; 2013 Mar; 13():10. PubMed ID: 23506523
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.
Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K
Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal and pleural fluids may appear hyperintense on hepatobiliary phase using hepatobiliary MR contrast agents.
Ciolina M; Di Martino M; Bruno O; Pommier R; Vilgrain V; Ronot M
Eur Radiol; 2018 Jul; 28(7):3020-3031. PubMed ID: 29374320
[TBL] [Abstract][Full Text] [Related]
16. Partition coefficients for gadolinium chelates in the normal myocardium: comparison of gadopentetate dimeglumine and gadobenate dimeglumine.
Kawel N; Nacif M; Santini F; Liu S; Bremerich J; Arai AE; Bluemke DA
J Magn Reson Imaging; 2012 Sep; 36(3):733-7. PubMed ID: 22488770
[TBL] [Abstract][Full Text] [Related]
17. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Gd-Bz-TTDA, Gd-EOB-DTPA, and Gd-BOPTA for dynamic MR imaging of the liver in rat models.
Jaw TS; Chen SH; Wang YM; Hsu JS; Kuo YT; Chiu YY; Tsai KB; Hsieh TJ; Liu GC
Kaohsiung J Med Sci; 2012 Mar; 28(3):130-7. PubMed ID: 22385605
[TBL] [Abstract][Full Text] [Related]
19. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.
Reimer P; Schneider G; Schima W
Eur Radiol; 2004 Apr; 14(4):559-78. PubMed ID: 14986050
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Gd-DTPA and Gd-BOPTA for studying renal perfusion and filtration.
Notohamiprodjo M; Pedersen M; Glaser C; Helck AD; Lodemann KP; Jespersen B; Fischereder M; Reiser MF; Sourbron SP
J Magn Reson Imaging; 2011 Sep; 34(3):595-607. PubMed ID: 21761461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
